Dianthus Therapeutics Inc (NASDAQ:DNTH) has a beta value of 1.53 and has seen 0.53 million shares traded in the recent trading session. The company, currently valued at $565.71M, closed the recent trade at $17.61 per share which meant it gained $0.78 on the day or 4.63% during that session. The DNTH stock price is -83.25% off its 52-week high price of $32.27 and 6.64% above the 52-week low of $16.44. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.25 million shares traded. The 3-month trading volume is 291.29K shares.
The consensus among analysts is that Dianthus Therapeutics Inc (DNTH) is Buy stock at the moment, with a recommendation rating of 1.17. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.71.
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
Sporting 4.63% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the DNTH stock price touched $17.61 or saw a rise of 13.89%. Year-to-date, Dianthus Therapeutics Inc shares have moved -19.22%, while the 5-day performance has seen it change -3.62%. Over the past 30 days, the shares of Dianthus Therapeutics Inc (NASDAQ:DNTH) have changed -11.33%. Short interest in the company has seen 5.57 million shares shorted with days to cover at 22.9.
Wall Street analysts have a consensus price target for the stock at $52, which means that the shares’ value could jump 66.13% from the levels at last check today. The projected low price target is $52.0 while the price target rests at a high of $52.0. In that case, then, we find that the latest price level in today’s session is -195.29% off the targeted high while a plunge would see the stock gain -195.29% from the levels at last check today.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
The company’s shares have lost -35.69% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -43.62%.
10 analysts offering their estimates for the company have set an average revenue estimate of 806.9k for the current quarter. 10 have an estimated revenue figure of 910.7k for the next ending quarter. Year-ago sales stood 874k and 1.86M respectively for this quarter and the next, and analysts expect sales will shrink by -7.68% for the current quarter and -43.62% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.14% over the past 5 years. Earnings growth for 2025 is a modest -33.43% while over the next 5 years, the company’s earnings are expected to decrease by -16.78%.
DNTH Dividends
Dianthus Therapeutics Inc is expected to release its next earnings report on 2025-Mar-10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Insiders own 8.07% of the company shares, while shares held by institutions stand at 114.24% with a share float percentage of 124.26%. Investors are also buoyed by the number of investors in a company, with Dianthus Therapeutics Inc having a total of 142.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 4.4 million shares worth more than $113.93 million. As of 2024-06-30, FMR LLC held 12.8624% of shares outstanding.
The other major institutional holder is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, with the holding of over 3.01 million shares as of 2024-06-30. The firm’s total holdings are worth over $77.99 million and represent 8.8042% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. As of Feb 28, 2025, the former fund manager holds about 2.90% shares in the company for having 931.62 shares of worth $16.31 million while later fund manager owns 785.32 shares of worth $13.75 million as of Dec 31, 2024, which makes it owner of about 2.44% of company’s outstanding stock.
